Method for treating abdominal discomfort

• US 7,795,312 B2
• Filed: 12/29/2003
• Issued: 09/14/2010
• Est. Priority Date: 12/27/2002
• Status: Active Grant

• Current Assignee: Sucampo GmbH (Mallinckrodt plc)
• Original Assignee: Sucampo AG (Mallinckrodt plc)
• Inventors: Ueno, Ryuji, Kuno, Sachiko
• Primary Examiner(s): Spivack; Phyllis G.
• Application Number:
  US10/745,689
• Publication Number:
  US 20040138308A1
• Time in Patent Office: 2,451 Days
• Field of Search: None
• US Class Current: 514/573
• CPC Class Codes: A61K 31/557 Eicosanoids, e.g. leukotrienes or prostaglandins
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 31/5585 having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/10 Laxatives
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07C 57/56 containing rings other than six-membered aromatic rings

Abstract

A method for treating irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E₁ or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E₁, or a salt, ether, ester or amide thereof, to the subject. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E₁ or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E₁, or a salt, ether, ester or amide thereof, to the subject.

Claims

1. A method for treating irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E₁, or a salt, ether, ester or amide thereof, to the subject.

2. The method as described in claim 1, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E₁, or a pharmaceutically acceptable salt, ester or amide thereof.

3. The method as described in claim 1, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μ

g/kg per day or a 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E₁ compound.

4. A method for treating as described in claim 2, wherein the administration is in the amount of 0.1-10 μ

g/kg per day.

5. The method as described in claim 1, which comprises systemic administration 1-4 times per day or continuous administration at the amount of 0.01-100 μ

g/kg per day.

6. The method as described in claim 5, wherein the administration is at the amount of 0.1-10 μ

g/kg per day.

7. A method for treating irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro prostaglandin E₁ or a salt, ether, ester or amide thereof, to the subject.

8. The method as described in claim 7, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E₁, or a pharmaceutically acceptable salt, ester or amide thereof.

9. The method for treating irritable bowel syndrome in a as described in claim 8, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μ

g/kg per day.

10. The method as described in claim 8, wherein the administration is in the amount of 0.1-10 μ

g/kg per day.

11. The method as described in claim 7, which comprises systemic administration 1-4 times per day or continuous administration at the amount of 0.01-100 μ

g/kg per day.

12. The method as described in claim 7, wherein the administration is at the amount of 0.1-10 μ

g/kg per day.

13. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E₁, or a salt, ether, ester or amide thereof, to the subject.

14. The method as described in claim 13, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E₁, or a pharmaceutically acceptable salt, ester or amide thereof.

15. The method as described in claim 14, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μ

g/kg per day.

16. The method as described in claim 13, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μ

g/kg per day.

17. The method as described in claim 13, wherein the administration is in the amount of 0.1-10 μ

g/kg per day.

18. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro prostaglandin E₁, or a salt, ether, ester or amide thereof, to the subject.

19. The method as described in claim 18, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E₁, or a pharmaceutically acceptable salt, ester or amide thereof.

20. The method as described in claim 19, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μ

g/kg per day.

21. The method as described in claim 18, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μ

g/kg per day.

22. The method as described in claim 18, wherein the administration is in the amount of 0.1-10 μ

g/kg per day.